UNCY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 16:00):

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury...

Stats
Today's Volume	535 286
Average Volume	363 270
Market Cap	38.93M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.180 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.880
ATR14	$0.0100 (0.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-05	Laumas Sandeep	Buy	189 236	Stock Options
2023-09-05	Kenkare-mitra Sara	Buy	180 000	Stock Options
2023-09-05	Ryan John L	Buy	112 147	Stock Options
2023-09-05	Aggarwal Gaurav	Buy	180 000	Stock Options
2023-09-05	Kenkare-mitra Sara	Buy	0

INSIDER POWER
99.84
Last 53 transactions
Buy: 69 902 764 \| Sell: 337 849

Volume Correlation

Long: -0.13 (neutral)

Short: 0.40 (neutral)

Signal:(49.305) Neutral

Unicycive Therapeutics, Correlation

10 Most Positive Correlations
BPTS	0.899
IONM	0.888
SFT	0.887
DFPH	0.871
VOSOU	0.87
TMTS	0.87
PPGHU	0.862
NYMT	0.85
ENSC	0.841
MRAC	0.841

10 Most Negative Correlations
CMLT	-0.954
ITAC	-0.937
CFACU	-0.931
CENH	-0.927
GCAC	-0.921
GIAC	-0.92
MCAE	-0.919
CMLTU	-0.915
CTAC	-0.904
GLADL	-0.9

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Unicycive Therapeutics, Correlation - Currency/Commodity

-0.53
( weak negative )

-0.57
( weak negative )

0.00
( neutral )

-0.61
( weak negative )

0.00
( neutral )

0.58
( weak )

Unicycive Therapeutics, Financials

Annual	2023
Revenue:	$675 000
Gross Profit:	$391 000 (57.93 %)
EPS:	$-1.240

Q4	2023
Revenue:	$0
Gross Profit:	$-82 000.00 (0.00 %)
EPS:	$-0.220

Q3	2023
Revenue:	$0
Gross Profit:	$-79 000.00 (0.00 %)
EPS:	$-0.130

Q2	2023
Revenue:	$0
Gross Profit:	$-78 000.00 (0.00 %)
EPS:	$-0.250

Financial Reports:

No articles found.

Unicycive Therapeutics,